The clinical trial, sponsored by the Chinese PLA General Hospital, is investigating an innovative allogeneic STAR T cell therapy for relapsed/refractory B-cell non-Hodgkin's lymphoma (B-NHL). The use of CRISPR-Cas9 technology to enhance T cell efficacy while minimizing graft-versus-host disease (GvHD) positions this therapy as a potentially competitive option in the CAR-T landscape. The market for B-NHL therapies is substantial, with increasing demand for effective treatments in relapsed cases. The trial's focus on multiple B-NHL subtypes broadens its potential patient population, enhancing commercial viability. However, the competitive landscape includes established CAR-T therapies and emerging TCR therapies, necessitating careful monitoring of clinical outcomes and market reception.